Fullerenes versus AIDS

from the go-fullerenes dept.
From PR Newswire on Yahoo comes this news from Toronto: "William Multi-Tech Inc., (“Multi-Tech'') (TSE:WIM – news) announced today that C Sixty Inc. (“C Sixty'') a privately held biotechnology company, in which Multi-Tech has a 40% ownership interest, has begun upscale manufacturing of its lead fullerene based drug candidate for treatment of patients with AIDS and AIDS related disease. As a novel anti-HIV drug, C Sixty's product has to date demonstrated potent activity against multiple strains of the HIV virus including drug resistant and de-novo resistant strains of the virus…The potential for widespread applications of C Sixty's technology in medicine, positions the company as a leader in the emerging field of Nanotechnology and its related Biotechnology market. "

Leave a comment

    Your Cart
    Your cart is emptyReturn to Shop